awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35583692-384BCC88-39CC-47BC-B142-66C6095FB2DF
Q35583692-384BCC88-39CC-47BC-B142-66C6095FB2DF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35583692-384BCC88-39CC-47BC-B142-66C6095FB2DF
Once-daily therapy: less is more.
P2860
Q35583692-384BCC88-39CC-47BC-B142-66C6095FB2DF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35583692-384BCC88-39CC-47BC-B142-66C6095FB2DF
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
57e56de49b4ef551d1edec4cf062077d8dbd7eba
P2860
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.